BSc CPA - Kintara Therapeutics CFO Sec
| KTRADelisted Stock | USD 6.30 0.14 2.17% |
Insider
BSc CPA is CFO Sec of Kintara Therapeutics
| Age | 55 |
| Phone | 858 350 4364 |
| Web | https://www.kintara.com |
Kintara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.0376) % which means that it has lost $1.0376 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.7077) %, meaning that it created substantial loss on money invested by shareholders. Kintara Therapeutics' management efficiency ratios could be used to measure how well Kintara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Kintara Therapeutics currently holds 2.44 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Kintara Therapeutics has a current ratio of 3.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Kintara Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Andrew Guttadauro | Oncolytics Biotech | 57 | |
| Carl Langren | Lumos Pharma | 69 | |
| Mark Newman | GeoVax Labs | 69 | |
| Steven CPA | Theriva Biologics | 63 | |
| CPA CPA | Cellectar Biosciences | 60 | |
| Joseph Hazelton | Dyadic International | 48 | |
| Lori CPA | Lumos Pharma | 40 | |
| Christine MBA | SAB Biotherapeutics | 68 | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| Lisa Miller | Lumos Pharma | N/A | |
| Karen Bergman | Bolt Biotherapeutics | N/A | |
| Elizabeth Evans | Vaccinex | 51 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Steven JD | Longboard Pharmaceuticals | 59 | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| Steven Ruhl | Forte Biosciences | 67 | |
| Edward DVM | SAB Biotherapeutics | N/A | |
| Edgar MD | Bolt Biotherapeutics | 78 | |
| Jon Patton | Oncolytics Biotech | N/A | |
| McKee MD | GeoVax Labs | 72 | |
Management Performance
| Return On Equity | -3.71 | |||
| Return On Asset | -1.04 |
Kintara Therapeutics Leadership Team
Elected by the shareholders, the Kintara Therapeutics' board of directors comprises two types of representatives: Kintara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kintara. The board's role is to monitor Kintara Therapeutics' management team and ensure that shareholders' interests are well served. Kintara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kintara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BSc CPA, CFO Sec | ||
| BBA CPA, CEO Pres | ||
| BSc MA, CoFounder Officer | ||
| Greg Johnson, Acting Operations | ||
| CPA BBA, CEO and Presidentident |
Kintara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kintara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.71 | |||
| Return On Asset | -1.04 | |||
| Current Valuation | 17.98 M | |||
| Shares Outstanding | 55.66 M | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 1.47 % | |||
| Number Of Shares Shorted | 5.43 M | |||
| Price To Book | 7.81 X | |||
| EBITDA | (8.5 M) | |||
| Net Income | (8.32 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |